Indoramin in the treatment of prostatic bladder outflow obstruction.
A series of 40 patients took part in a double-blind, placebo-controlled trial of indoramin in prostatic bladder outflow obstruction. Patients were assessed clinically and urodynamically before and after 4 weeks' treatment. Significant improvement was seen in nocturia, volume voided, flow rates and residual urine. The drug was well tolerated, although 7 patients on treatment and 7 on placebo noted side effects. These results suggest that indoramin may be a useful agent in the symptomatic management of bladder outflow obstruction.
Stott
M A
MA
Urodynamic Unit, Ham Green Hospital, Bristol.
Abrams
P
P
D004311:Double-Blind Method; D006801:Humans; D007217:Indoramin / Q000627:therapeutic use*; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications*; D001743:Urinary Bladder / Q000503:physiopathology; D001748:Urinary Bladder Neck Obstruction / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014563:Urodynamics
D007217:Indoramin